[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@Generic_Tina Tina Banerjee

Tina Banerjee posts on X about future, $4516t, $4523t, cro the most. They currently have XX followers and XX posts still getting attention that total X engagements in the last XX hours.

Engagements: X #

• X Week XX -XX%
• X Month XXX -XX%
• X Months XXXXX +88%
• X Year XXXXXX +268%

Mentions: X #

• X Week XX -XX%
• X Month XX -XX%
• X Months XXX +46%
• X Year XXX +221%

Followers: XX #

• X Week XX +1.80%
• X Month XX no change
• X Months XX +35%
• X Year XX +45%

CreatorRank: undefined #

Social Influence

Social category influence finance XXXX% countries XXXX% technology brands XXXX% stocks XXXX%

Social topic influence future 11.76%, $4516t 5.88%, $4523t 5.88%, cro 5.88%, filed 5.88%, core 5.88%, china 5.88%, samsung 5.88%, strong 5.88%, asia XXXX%

Top Social Posts

Top posts by engagements in the last XX hours

"Nippon Shinyaku and Capricor announce positive Phase X results for Deramiocel with potential FDA approval and commercialization on the horizon. Near term concerns with Viltepso remain"
X Link 2025-12-08T00:35Z XX followers, XX engagements

"Takeda and Eisai witnessed clinical trials setback. Wuxi AppTec is selling China-based CRO subsidiaries. CSL is delaying demerger of CSL Seqirus. PharmaEssentia filed label expansion of Besremi in US"
X Link 2025-11-02T00:35Z XX followers, XXX engagements

"Innovent Biologics reports 1H25 results with XX% revenue growth and maiden net profit driven by core oncology product Tyvyt. Mazdutide approval in China along witth Tyvyt to drive future growth"
X Link 2025-11-24T14:48Z XX followers, XX engagements

"Simcere stuck license pact with Vigonvita. Kelun Bio inked partnership with Crescent Biopharma. Samsung Biologics is acquiring land for third campus. Biocon settled with Amgen for Prolia biosimilar"
X Link 2025-12-07T00:35Z XX followers, XX engagements

"Santen Pharma sees revenue and profits decline in H1FY26. Expects strong H2FY26 with growth in EMEA and Asia driving overseas business rise. Drug development and market leadership future accretive"
X Link 2025-12-11T00:35Z XX followers, XX engagements